The role of vaccines in the COVID-19 pandemic: what have we learned?
F Krammer - Seminars in Immunopathology, 2024 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and
caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed …
caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed …
COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
AA Zasada, A Darlińska, A Wiatrzyk, K Woźnica… - Viruses, 2023 - mdpi.com
The outbreak of COVID-19 started in December 2019 and spread rapidly all over the world.
It became clear that the development of an effective vaccine was the only way to stop the …
It became clear that the development of an effective vaccine was the only way to stop the …
Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
JA Williams, M Biancucci, L Lessen, S Tian… - Science …, 2023 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern
challenge the efficacy of approved vaccines, emphasizing the need for updated spike …
challenge the efficacy of approved vaccines, emphasizing the need for updated spike …
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA …
ME Toledo-Romaní, M García-Carmenate… - The Lancet Regional …, 2023 - thelancet.com
Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD
conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity …
conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity …
[HTML][HTML] Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor …
R Puga-Gómez, Y Ricardo-Delgado… - International Journal of …, 2023 - Elsevier
Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r-receptor binding domain (RBD) protein vaccines. Methods A …
combining two SARS-CoV-2r-receptor binding domain (RBD) protein vaccines. Methods A …
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals
Background This study aimed at evaluation and comparison of PastoCovac Plus protein-
subunit vaccine in parallel with ChAdOx1-S (AstraZeneca) and BBIBP-CorV (Sinopharm) in …
subunit vaccine in parallel with ChAdOx1-S (AstraZeneca) and BBIBP-CorV (Sinopharm) in …
Recombinant protein vaccines against human betacoronaviruses: strategies, approaches and progress
A Kovalenko, E Ryabchevskaya, E Evtushenko… - International Journal of …, 2023 - mdpi.com
Betacoronaviruses have already troubled humanity more than once. In 2002–2003 and
2012, the SARS-CoV and MERS-CoV, respectively, caused outbreaks of respiratory …
2012, the SARS-CoV and MERS-CoV, respectively, caused outbreaks of respiratory …
A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19
Exposure to severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) prompts
humoral immune responses in the human body. As the auxiliary diagnosis of a current …
humoral immune responses in the human body. As the auxiliary diagnosis of a current …
Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens
T Boggiano-Ayo, J Palacios-Oliva… - … in Bioengineering and …, 2023 - frontiersin.org
We have developed a single process for producing two key COVID-19 vaccine antigens:
SARS-CoV-2 receptor binding domain (RBD) monomer and dimer. These antigens are …
SARS-CoV-2 receptor binding domain (RBD) monomer and dimer. These antigens are …
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic …
M Barkhordar, B Chahardouli, A Biglari… - Frontiers in …, 2023 - frontiersin.org
Background Allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients must be
vaccinated against SARS-CoV-2 as quickly as possible after transplantation. The difficulty in …
vaccinated against SARS-CoV-2 as quickly as possible after transplantation. The difficulty in …